Lifecore Biomedical (NASDAQ:LFCR) held its second-quarter earnings conference call on Wednesday. Bel

CHASKA, Minn., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore

Are RXO, PTC, LFCR, WAFD Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Oct. 5, 20

BALA CYNWYD, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the followi

EQUITY ALERT - The M&A Class Action Firm Launches Inquiry -- FWAC, MGLD, LFCR, and MGPR NewswireNEW

Major M&A deals include Valley National buys Bluevine, Roland Foods buys Savor Brands, Bloomberg

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti,

BALA CYNWYD, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the follow

https://www.sec.gov/Archives/edgar/data/1005286/000110465926111939/xslSCHEDULE_13D_X02/primary_doc.x

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lifecore Biomedical, Inc.

NEW YORK, Sept. 29, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Ass

Barrington Research analyst Michael Petusky downgrades Lifecore Biomedical (NASDAQ:LFCR) from Out

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - September 29, 2026) - Law office of Brodsky & Smith ann

What happened Lifecore Biomedical, Inc. (NASDAQ: LFCR) said on September 28, 2026, that it entered a

Gainers Kodiak Sciences (NASDAQ:KOD) shares moved upwards by 172.3% to $88.08 during Monday's r

Lifecore shareholders will receive just $6.28 per share in a transaction valued at up to $663.7 mill

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Lifecore Biomedical, Inc

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale

Lifecore Common Stockholders to Receive $6.28 per Share in Cash at Closing, Representing a 49.5% Pre

Lifecore Common Stockholders to Receive $6.28 per Share in Cash at Closing, Representing a  49.5% Pr

CHASKA, Minn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecor

-- Significant New Program Positioned to Become One of Lifecore's Largest Contracts -- -- Agreement

Lifecore Biomedical, Inc. (LFCR) Q2 2026 Earnings Call Transcript

Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.19) per share which beat the anal

Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $120.000 million-$125.000 millio

-- Reaffirms 2026 Guidance -- -- Multiple New Business Wins, Adding Impactful Programs to Pipeline -

CHASKA, Minn., July 29, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecor

Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Ou

-- Agreement Calls for Tech Transfer in Preparation for Potential Commercial Manufacturing of Inject

Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $120.000 million-$125.000 millio

Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.43) per share which missed the an

Barrington Research analyst Michael Petusky maintains Lifecore Biomedical (NASDAQ:LFCR) with a Ou

Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated injectables contrac

Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.16) per share. This is a 20 perce

Barrington Research analyst Michael Petusky upgrades Lifecore Biomedical (NASDAQ:LFCR) from Marke

Lifecore stock plunges after earnings miss and weak 2026 outlook, with customer losses and delayed g

Lifecore Biomedical (NASDAQ:LFCR) sees FY2026 sales of $120.000 million-$125.000 million vs $129.846

Indomo Developing Fast-Acting, At-Home Treatment for Inflammatory Acne Lesions to be Administered wi

Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract developmen

Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $74.000 million-$76.000 million

Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.29) per share which beat the anal

Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract developmen

Keybanc analyst Paul Knight initiates coverage on Lifecore Biomedical (NASDAQ:LFCR) with a Sector